TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA has opened a public request for information on how early-phase clinical trials of ibogaine drug products should be designed. It is seeking input on study populations, dosing, safety protections and oversight; the agency says the process is intended to inform research, not establish ibogaine as a treatment.
The U.S. Food and Drug Administration on October 5 announced a request for information on how to design early-phase clinical trials of ibogaine drug products, asking researchers, patients and other stakeholders for data and comments on dosing, safety and study oversight. The agency says the input could help shape research approaches, while noting that ibogaine raises serious safety concerns and that its potential benefits and risks remain under investigation.
The FDA is inviting comments on four broad areas: study design and patient populations; dose selection and escalation; safety precautions; and ethical and independent oversight. The request covers practical protocol questions, including care settings, eligibility criteria, safety monitoring and rules for stopping a trial.
On dosing, the agency is seeking feedback on a proposed approach using small, sequential groups whose doses increase gradually. It also asks about a starting dose supported by available data and capped at 10 milligrams per kilogram. The FDA has not said that this approach is a final requirement or approved protocol; the RFI is intended to gather information on approaches it is considering.
Safety questions include monitoring for cardiac and neurologic adverse events and other safeguards for participants. The request also seeks input on informed consent and independent safety oversight. The FDA says information submitted may help it better understand possible uses, benefits and risks of ibogaine drug products and inform future drug-development approaches.
How Trial Design Could Change
The request could influence how sponsors and researchers plan initial studies of ibogaine, a step that matters because early-phase trials assess safety and help determine whether further clinical research is warranted. Feedback on dose escalation, participant eligibility and monitoring could inform how risks are assessed before larger or later-stage studies are considered.
The agency’s focus on cardiac and neurologic risks means the discussion is not simply about whether ibogaine might be studied. It is also about the conditions under which research could proceed and what protections participants would need. The FDA said patients with serious conditions and unmet treatment needs merit rigorous investigation, while emphasizing that patient safety must come first.
The RFI itself does not authorize a treatment for routine use, establish that ibogaine is effective for any condition, or amount to a decision that a particular trial design is safe. It is an opportunity to collect evidence and views that may inform regulatory thinking. For patients and families, the distinction matters: federally supported research is under way or being planned, but the announcement does not make ibogaine an FDA-approved therapy.
ibogaine clinical trial safety monitoring kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Federal Ibogaine Research Plans
The FDA described the RFI as its latest action related to President Donald Trump’s April 2026 executive order on accelerating medical treatments for serious mental illness, which directed agencies to accelerate research into psychedelic medicine. The current request focuses on ibogaine drug products and the design of their early clinical investigation.
In July 2026, the FDA issued final industry guidance titled Psychedelic Drugs: Considerations for Clinical Investigations, offering general considerations for sponsors developing psychedelic drugs. The agency also said it had allowed an early-phase study of noribogaine hydrochloride, an ibogaine derivative, to proceed under an Investigational New Drug application for potential study in alcohol use disorder. Permission for a study to proceed is not the same as FDA approval of the drug or proof that it works.
Other federal efforts include an HHS program funded through the Advanced Research Projects Agency for Health to collect safety and efficacy data in early-phase trials, and National Institute on Drug Abuse-funded research on ibogaine for potential treatment of opioid use disorder. HHS has identified adults with opioid use disorder and post-traumatic stress disorder as initial populations for federally supported research, based on available data and the seriousness of those conditions.
“Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches.”
— Michael Davis, director of the FDA Center for Drug Evaluation and Research
cardiac monitoring devices for clinical trials
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evidence and Risks Still Under Review
The RFI does not resolve whether ibogaine is safe or effective for opioid use disorder, PTSD or any other condition. The FDA’s announcement does not provide trial results establishing a benefit, nor does it identify a final trial protocol or a decision about whether a particular ibogaine product will be approved.
The agency is seeking input because questions remain about dose, eligible participants, monitoring and safety oversight. The extent to which public submissions will change the FDA’s proposed approaches, and what studies may follow, is not yet clear. The announcement identifies cardiac and neurologic events as safety concerns but does not quantify their frequency or provide a full account of the available evidence.
Noribogaine’s study authorization is specific to an early-phase investigation under an Investigational New Drug application. It should not be read as approval of ibogaine or noribogaine for general treatment. The FDA has not announced in this release when it will publish a review of the comments or any resulting regulatory decisions.
neurologic adverse event monitoring equipment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How to Submit FDA Comments
The FDA is accepting comments, data and information for 45 days after publication of the request in the Federal Register. The agency lists the closing date as Friday, November 20, 2026, and says late submissions will not be considered.
Comments can be submitted electronically through Regulations.gov by searching for Docket No. FDA-2026-N-10429. Written submissions may be mailed to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, Maryland, 20852.
After the comment period, the FDA may use submissions to inform its thinking about early-phase trial design and ibogaine drug development. The announcement does not set a date for a response or describe a specific next regulatory action, so further milestones have not been confirmed.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the FDA asking the public to comment on?
The agency seeks comments, data and information on early-phase ibogaine trial design, including patient populations, dosing, care settings, eligibility, safety monitoring, stopping rules, informed consent and independent oversight.
Does this announcement mean ibogaine is FDA-approved?
No. The request for information is not an approval or a finding that ibogaine is effective. It is intended to help the FDA assess possible research approaches and the drug products’ potential uses, benefits and risks.
What dose approach is the FDA asking about?
The FDA is seeking feedback on small, sequential dose-ascending groups and a starting dose justified by available data, with a proposed ceiling of 10 mg/kg. The request asks for input; it does not establish a final dosing protocol.
When and how can people submit comments?
The stated deadline is November 20, 2026. The FDA directs electronic commenters to Regulations.gov, where they can search for Docket No. FDA-2026-N-10429; paper submissions can be mailed to the agency’s Dockets Management Staff in Rockville, Maryland.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
